Proteoforms, the diverse molecular variants of proteins, are key to understanding cellular functions, disease mechanisms, and biomarker discovery in proteomics.

Non-CHO cell expression systems gain traction as faster, more flexible alternatives for biologics manufacturing.

Built on groundbreaking research from Israel ’s Weizmann Institute of Science, Promise Bio developed the first cloud-based platform for broad epiproteomics, helping researchers uncover disease ...

New panel expands coverage for Alzheimer’s and Parkinson’s diseases including 15 new biomarkers developed with support from ...

Cas9, Transcription Activator-Like Effector Nucleases (TALENs), and Zinc-Finger nucleases (ZFNs) have demonstrated great utility, primarily for genetic knock-out applications, none have been adopted ...

Few drugs have entered mainstream awareness as quickly or as dramatically as glucagon-like peptide-1, or GLP-1 receptor agonists. Initially approved by the FDA for the treatment of type 2 diabetes, ...

New panel expands coverage for Alzheimer's and Parkinson's diseases including 15 new biomarkers developed with support from The Michael J. Fox Foundation for Parkinson's Research (MJFF) and 12 assays ...

A cluster of recent studies has sharpened the scientific picture of how T cells switch on, tracking the molecular signals ...

GLP-1s are building a reputation as "wonder drugs." First characterized for their ability to improve insulin release and treat diabetes, the drugs were later found to promote weight loss and improve ...